Are we prepared for emerging flaviviruses in Europe? Challenges for vaccination.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
TitleAre we prepared for emerging flaviviruses in Europe? Challenges for vaccination.
Published inHum Vaccin Immunother 2018; 14(2):337-44
PubliekssamenvattingTick-borne encephalitis and West Nile fever are endemic flavivirus diseases in Europe. Climate change, virus evolution, and social factors may increase the risk of these flavivirus infections and may lead to the emergence of other flaviviruses in Europe that are endemic in (sub)tropical regions of the world. Control of the spread of flaviviruses is very difficult considering the cycling of flaviviruses between arthropod vectors and animal reservoir hosts. The increasing threat of flavivirus infections emphasizes the necessity of a sustainable vector surveillance system, an active animal health surveillance system and an adequate human surveillance system for early detection of flavivirus infections. Vaccination is the most important approach to prevent flavivirus infections. Effective inactivated whole virus vaccines against tick-borne encephalitis (TBE) infection are available. Implementation of TBE vaccination based on favorable cost-effectiveness estimates per region and per target group can reduce the disease burden of TBE infection. At present, several West Nile virus (WNV) vaccine candidates are in various stages of clinical development. A major challenge for WNV vaccine candidates is to demonstrate efficacy, because of the sporadic nature of unpredictable WNV outbreaks. Universal WNV vaccination is unlikely to be cost-effective, vaccination of high-risk groups will be most appropriate to protect against WNV infections.
- A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available.
- Authors: Ishikawa T, Yamanaka A, Konishi E
- Issue date: 2014 Mar 10
- Research advances in plant-made flavivirus antigens.
- Authors: Martínez CA, Giulietti AM, Talou JR
- Issue date: 2012 Nov-Dec
- Advances in flavivirus vaccine development.
- Authors: Coller BA, Clements DE, Martyak T, Yelmene M, Thorne M, Parks DE
- Issue date: 2010 Dec
- West Nile and Usutu Virus Infections and Challenges to Blood Safety in the European Union.
- Authors: Domanović D, Gossner CM, Lieshout-Krikke R, Mayr W, Baroti-Toth K, Dobrota AM, Escoval MA, Henseler O, Jungbauer C, Liumbruno G, Oyonarte S, Politis C, Sandid I, Vidović MS, Young JJ, Ushiro-Lumb I, Nowotny N
- Issue date: 2019 Jun
- Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines.
- Authors: Eckels KH, Putnak R
- Issue date: 2003